

PRESS RELEASE

innate pharma

INNATE PHARMA ANNOUNCES ITS FINANCIAL CALENDAR FOR 2013 AS WELL AS ITS PARTICIPATION TO UPCOMING INVESTOR CONFERENCES

Marseilles, France, December 19, 2012

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces today its tentative financial calendar for 2013, which is set as follows:

- February 7, 2013: Publication of revenue for 4Q2012 and for the 2012 fiscal year, with management comments.
- March 5, 2013: Publication of 2012 financial statements, with management comments. *The 2012 Reference Document and Financial Report (included in the Reference Document) will be released during the second quarter of 2013.*
- May 7, 2013: Publication of revenue for 1Q2013, with management comments.
- June 28, 2013: Annual shareholders meeting in Marseilles.
- September 19, 2013: Publication of mid-year financial statements as of June 30, 2013, with management comments.
- November 5, 2013: Publication of revenue for 3Q2013, with management comments.


During the first quarter of 2013, Innate Pharma management will be present at the following investor conferences:

JP Morgan Healthcare conference - San Francisco, January 7, 8 & 9, 2013;

Oddo Midcap Forum – Lyon, January 11, 2013;

Credit Suisse London One-on-One Healthcare Conference – London, March 6, 2013.

Innate Pharma is committed to meet on a regular basis with the financial community. Investors can also find updated information on the company's website (www.innate-pharma.com). All corporate information on the Company such as its financial statements or its corporate presentations is available on the Company's website, in the Investors' section (<http://www.innate-pharma.com/financials>).



PRESS RELEASE

innate pharma

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approach has been validated by licence agreements with two major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 81 employees as at September 30, 2012.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code FR0010331421
Ticker code IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma

Laure-Hélène Mercier
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
investors@innate-pharma.com

ATCG Press

Marielle Bricman
Mob.: +33 (0)6 26 94 18 53
mb@atcg-partners.com